January 25, 2022
Life Sciences
  • Pfizer Inc. and BioNTech SE said they are testing a version of their COVID-19 vaccine that targets the Omicron variant. Pfizer said results are expected in the first half of the year so that an Omicron-specific vaccine is available “should it be needed.” Separately, a preprint study indicates that immune protection against Omicron persists at least four months after a Pfizer-BioNTech booster. (Articles here, here, and here)